SCHEMBL10128249

SCHEMBL10128249

Cc1ccc(S(=O)(=O)C(C)C)c(Nc2nc(NCC3(N)CCCCC3)[nH]c(=O)c2C(N)=O)c1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.34
KCNH2 Q12809 1/20 0.32
ALK Q9UM73 6/20 0.32
INSR P06213 3/20 0.32
CXCR2 P25025 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10128253 0.94 SYK (0.34) SYKKCNH2ALKINSRCXCR2
SCHEMBL10128205 0.90 ALK (0.39) ALKINSR
SCHEMBL10128146 0.90 ALK (0.39) ALKINSR
SCHEMBL10128144 0.89 ALK (0.40) ALKINSR
SCHEMBL10128309 0.82 SYK (0.38) SYKALK
SCHEMBL16303171 0.80 SYK (0.33) SYK
SCHEMBL282380 0.80 ADRA2A (0.38) ALKINSR
SCHEMBL10128744 0.80 SYK (0.38) SYKKCNH2
SCHEMBL10128441 0.80 SYK (0.35) SYKKCNH2
SCHEMBL10128122 0.79 ADRA2A (0.38) ALKINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 SYK 2200/4885KCNH2 2712/4885ALK 2/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 SYK 2200/4885KCNH2 2712/4885ALK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.